What's New in ADHD Research (Jul 27-Aug 2)

Illustration of a stack of highlighted research article cards fanned out with a magnifying glass resting on top, representing a weekly roundup of ADHD research news

If you try to keep up with ADHD news, it is easy to feel like something is always happening and nothing sticks.

Five things from the last week are worth actually knowing, not just scrolling past. A new kind of medication. New evidence about how ADHD plays out across a life. A study that quietly undercuts one of the most common app pitches out there. And a reminder that diagnosis gaps have not closed just because diagnoses are rising.

This is the first edition of a new weekly roundup: the ADHD research and news actually worth reading, checked against the original source before it gets a mention here. Subscribe at the bottom to get the next one.

A new kind of ADHD medication just cleared the FDA

On July 24, 2026, the FDA approved centanafadine, sold as Simtriyo, for ADHD in adults and children aged 6 and up who weigh at least 20 kilograms.

Otsuka, the manufacturer, describes it as the first drug in a new class: a norepinephrine, dopamine, and serotonin reuptake inhibitor, distinct from both stimulants and the existing non-stimulant options.

The approval rests on four Phase 3 trials. In adult studies, both dose groups showed statistically significant symptom improvement compared to placebo, with effects appearing as early as week one. Pediatric and adolescent trials showed the same pattern at the higher dose.

It is not available yet. The drug still needs scheduling by the DEA before pharmacies can carry it.

And a new option existing is not the same as it being the right option for you. Whether to try it, and when, is a conversation with your prescriber, not something a blog post can answer.

What the evidence says about ADHD across a life

Three separate pieces of research, all making news this week, point at the same question from different angles: what does ADHD actually cost, cumulatively, over decades.

A Dutch research team published the longest follow-up of its kind. 154 adults diagnosed with ADHD in childhood, tracked alongside 138 of their siblings without ADHD and 129 unrelated people with no family history of it, re-assessed after an average of 17.6 years, at an average age of 28 to 29.

Major depressive disorder was diagnosed in 18% of the group with childhood ADHD, compared to 8% of unrelated controls and 6% of siblings. Adults with childhood ADHD scored worse than controls on more than 60% of everything the researchers measured. But 45% still met full diagnostic criteria for adult ADHD, which means 55% did not. Persistence is common in this group. It is not universal.

Separately, a Finnish twin study followed between 602 and 1,330 twins from adolescence into early midlife, using teacher assessments and diagnostic interviews at age 14. Adolescent ADHD symptoms were consistently linked to a higher risk of antisocial symptoms and criminal behavior later in life. Comparing twins within the same pair, a way of controlling for shared genes and upbringing, the researchers found the link mostly held up anyway. Higher cognitive ability did not protect against it either.

And this week a well known ADHD researcher revisited a UK cohort study from last year at a conference: adults with a recorded ADHD diagnosis lost an estimated 6.78 years of life expectancy for men and 8.64 years for women, compared to matched people without the diagnosis, drawn from primary care records covering over 9.5 million people. The study could not identify cause of death, so it cannot say why, only that the gap exists.

None of these three studies proves what will happen to any one person. They are population averages from specific cohorts, not individual forecasts. Taken together, they are still a reason to take ADHD seriously as a long-term health factor rather than only a childhood or workplace issue.

How ADHD traits complicate automatic learning

A study published this week in the Journal of Attention Disorders looked at something more specific: the tradeoff between deliberate self-control and the kind of learning that happens without you noticing.

226 university students did a reaction-time task that measured both. Normally, weaker inhibitory control comes with a small silver lining: people who are worse at consciously suppressing responses tend to be better at picking up hidden patterns automatically. In participants with higher self-reported ADHD traits, that silver lining disappeared. Their inhibitory control was worse, as expected, but the automatic-learning boost that usually comes with it did not show up.

The sample was young, mostly female, and highly educated, and relied on self-reported traits rather than a clinical diagnosis, so this is a lead rather than a settled finding. It points at something specific worth watching for in future research: it may not just be that self-control is harder with ADHD, but that the usual backup system does not fully compensate.

A brain-training app made people feel sharper. The tests disagreed.

A crossover trial gave 77 adults with ADHD, aged 18 to 60, twelve weeks on the NeuroNation MED cognitive training app. Three sessions a week, 30 to 40 minutes each, across 23 exercises.

Half started immediately, half waited and trained second, so everyone eventually got the same twelve weeks.

Afterward, people reported feeling better. Quality of life, attention, memory, and executive function all improved on self-report, most of all for people who started with the lowest scores.

Then the objective side. Reaction time and focus scores on standard cognitive tests barely moved. Core ADHD symptoms, hyperactivity, impulsivity, inattention, showed no meaningful change either.

That gap is the actual finding. Feeling sharper and measurably improving are not the same thing, and the distance between them is exactly where a lot of app marketing lives.

It is a reason to ask, of anything that promises to train your brain: sharper according to what, and measured how.

Diagnosis gaps are still wide, even as diagnoses rise

A study from researchers at the University of Liverpool, covered widely this week, used English primary care records covering 3.5 million patients in 2025 and 42.2 million over the prior 24 years to check whether rising ADHD diagnosis numbers actually closed the diagnosis gap.

New diagnoses more than doubled between 2021 and 2024. Recorded prevalence still sits at 1.19% overall. Among men aged 18 to 24, that is roughly 28% lower than global estimates would predict. Among adults 65 and older, recorded prevalence is over 90% lower than expected, which reads less like older adults having less ADHD and more like a generation that was never screened for it.

More diagnoses is not the same as fewer missed cases. Both things are true about England's numbers at once.

The takeaway

ADHD research is moving on more than one front at once. A genuinely new medication. Harder evidence about what ADHD costs across a life. A study that separates feeling better from measurably improving. And a reminder that rising diagnosis numbers do not mean the gap is closed.

None of it is a single fix. Read new claims against what was actually measured rather than how something made people feel, and bring anything medication-related to your prescriber rather than deciding it alone.